Paccal Vet Feline Cancer Trial
Now enrolling: A dose-finding study for cats with solid tumors
Fully funded study, no cost to pet owner
No placebo, all cats receive active treatment
Paccal Vet is based on a cancer drug widely used in human medicine
Cancer in cats
Solid tumors, including carcinomas, sarcomas, mast cell tumors and lymphomas in cats are often aggressive and can be difficult to treat with currently available treatment options. Despite how common and serious cancer is in cats, there are currently no chemotherapy drugs approved for use in cats.
This means veterinarians often have to rely on treatments that may not always work as well or be as safe for cats. As more cats live longer and cancer becomes more common, the need for cat-specific cancer treatments is becoming increasingly urgent.
Why is this study being done?
We are studying Paccal Vet as a possible new treatment option for cats with solid tumors.
Paccal Vet is a chemotherapy that has been specifically designed for pets, and it is based on a cancer drug that is widely used and approved in human cancer care.
Several clinical trials have been performed with Paccal Vet in dogs with promising results, but to date, no studies have evaluated Paccal Vet in cats.
The purpose of this study is to test the tolerability of Paccal Vet in cats and to determine an acceptable dose. A secondary, exploratory goal is to see whether Paccal Vet may have anti-cancer activity in various tumors in cats.
Why participate?
Give your cat access to a promising investigational drug based on a cancer drug that is widely used and approved in human cancer care
Benefit from regular medical check-ups and close monitoring during the study
Contributing to research that could benefit future feline cancer patients
What to Expect
The study has two parts: a screening phase and a treatment phase with regular check-ups.
Your cat may receive up to 4 doses of Paccal Vet therapy as part of the clinical trial. Each dose is given 3 weeks apart, so if your cat receives all doses, your cat will be participating for approximately 3 months.
Your cat will be closely monitored with health check-ups, blood tests, and quality of life surveys. This approach ensures close monitoring of your cat’s health and wellbeing and to see how the treatment is working.
All cats in this study will receive Paccal Vet. There is no placebo group in this study, therefore, if your cat is enrolled, he or she will be receiving the study drug.
Participating hospitals
Bridge Animal Referral Center, Edmonds, WA
Veterinary Referral Center of Central Oregon, Bend, OR
Take the survey to see if you may qualify
Contact us
Email: info@castr-alliance.com
Study management
CASTR Alliance was founded in 2019 by veterinary clinician-scientists Jessica Bertout and Jim Perry. As scientists, they bring extensive experience in designing, managing, and conducting clinical trials that meet the rigorous standards of the biotech industry. Moreover, as devoted pet owners and veterinarians, they are personally committed to delivering the highest quality care for our animal companions. Together, Drs. Bertout and Perry created CASTR Alliance to leverage their expertise and advance medicine for humans and animals alike.
Study sponsors
Vivesto is a Swedish drug development company that aims to offer new treatment options for hard-to-treat cancers where there are unmet medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet, which is being developed for the treatment of cancer in dogs and cats.
The Sugar Rub! Feline Cancer Foundation is a nonprofit organization dedicated to advancing research and awareness of feline cancers. Founded in 2024 by Jeanette in memory of her cat Sugar, who died of mammary cancer, the foundation promotes early detection through monthly “Sugar Rub” breast exams and supports research initiatives and clinical studies focused on feline oncology.